- Home
- OFS vs EPRX Comparison
OFS vs EPRX Comparison
Compare OFS & EPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OFS
- EPRX
- Stock Information
- Founded
- OFS 2001
- EPRX 2011
- Country
- OFS United States
- EPRX Canada
- Employees
- OFS N/A
- EPRX N/A
- Industry
- OFS Finance/Investors Services
- EPRX
- Sector
- OFS Finance
- EPRX
- Exchange
- OFS Nasdaq
- EPRX NYSE
- Market Cap
- OFS 110.3M
- EPRX 111.1M
- IPO Year
- OFS 2012
- EPRX N/A
- Fundamental
- Price
- OFS $8.83
- EPRX $3.90
- Analyst Decision
- OFS
- EPRX Strong Buy
- Analyst Count
- OFS 0
- EPRX 1
- Target Price
- OFS N/A
- EPRX $9.00
- AVG Volume (30 Days)
- OFS 57.1K
- EPRX 10.5K
- Earning Date
- OFS 05-01-2025
- EPRX 05-07-2025
- Dividend Yield
- OFS 15.67%
- EPRX N/A
- EPS Growth
- OFS N/A
- EPRX N/A
- EPS
- OFS 2.12
- EPRX N/A
- Revenue
- OFS $47,964,000.00
- EPRX N/A
- Revenue This Year
- OFS N/A
- EPRX N/A
- Revenue Next Year
- OFS N/A
- EPRX N/A
- P/E Ratio
- OFS $4.09
- EPRX N/A
- Revenue Growth
- OFS N/A
- EPRX N/A
- 52 Week Low
- OFS $7.75
- EPRX $2.20
- 52 Week High
- OFS $10.04
- EPRX $4.48
- Technical
- Relative Strength Index (RSI)
- OFS 55.08
- EPRX N/A
- Support Level
- OFS $8.20
- EPRX N/A
- Resistance Level
- OFS $8.66
- EPRX N/A
- Average True Range (ATR)
- OFS 0.42
- EPRX 0.00
- MACD
- OFS 0.03
- EPRX 0.00
- Stochastic Oscillator
- OFS 94.06
- EPRX 0.00
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.